Have the final results of the OPERA trial changed the way you approach organ preservation in rectal cancer?
Are you more inclined to offer brachytherapy boost instead of EBRT boost?
Answer from: Radiation Oncologist at Academic Institution
Great question. The OPERA results were certainly promising with 3-year organ preservation rates at 97% for tumors less than 3 centimeters. Patients neither received TME nor doublet chemotherapy (no oxaliplatin). Importantly, it was also the first randomized trial showing a higher dose of radiotherap...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
We will undoubtedly begin to develop this treatment further at our center. Centers in the US do not specialize in endorectal contact therapy the way that France in particular has for many decades. The OPERA trial is the climax of work started by Jean Pappion in the 1960s, continued by Prof Gerard in...
Comments
Radiation Oncologist at University of Florida
I spent a few weeks with Drs. Papillon and Gerard ...
I spent a few weeks with Drs. Papillon and Gerard ...
Radiation Oncologist at Memorial Sloan-Kettering Cancer Center
That was also what happened word for word at MDACC...
That was also what happened word for word at MDACC...
Radiation Oncologist at Lafayette Radiation Center
Link to Netherlands?
Link to Netherlands?
Radiation Oncologist at Memorial Sloan-Kettering Cancer Center
Actually, a group in the Netherlands also has a pu...
Actually, a group in the Netherlands also has a pu...
Answer from: Radiation Oncologist at Academic Institution
The 2022 ASCO abstract is a great jumping-off point, but reviewing the final publication will be essential before making any decisions about changes in practice. Let's re-engage when it is published! May 4, 2023:We're back! Final results are available: Gerard et al., PMID 36801007